Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac has initiated a Phase 1 clinical study for its modified COVID-19 mRNA vaccine candidate, CV0501, which targets the Omicron variant. This study aims to evaluate the safety and immunogenicity of CV0501 as a booster for previously vaccinated individuals. Conducted across clinical sites in the U.S., UK, Australia, and the Philippines, it plans to enroll up to 180 participants. This milestone underscores CureVac's commitment to advancing its second-generation vaccine technology in collaboration with GSK.
CureVac N.V. (Nasdaq:CVAC) announced that all proposals were approved during its annual general meeting, including the re-appointments and appointments of key supervisory and managing board members. Notable appointments include Craig Tooman, Dr. Debra Barker, and Dr. Klaus Schollmeier as supervisory board members, and Dr. Franz-Werner Haas and Dr. Malte Greune as managing directors. A detailed table of the voting results is expected soon. CureVac specializes in mRNA technology and collaborates with GSK on vaccine development.
CureVac N.V. (NASDAQ: CVAC) has acquired Frame Cancer Therapeutics for €32 million to enhance its oncology strategy. This acquisition will leverage Frame's advanced bioinformatics platform to identify unique neoantigens, potentially leading to innovative cancer vaccines. The acquisition involves a 50% upfront payment in CureVac shares, with additional payments tied to project milestones. The combined expertise is expected to accelerate the development of personalized and off-the-shelf cancer vaccines, strengthening CureVac's position in the oncology market.
CureVac N.V. (NASDAQ:CVAC) announced the appointment of Myriam Mendila as Chief Development Officer, effective February 1, 2023, succeeding Klaus Edvardsen, who will leave the company on June 30, 2022. Mendila brings over 20 years of experience in product development and oncology. Until her start date, Ulrike Gnad-Vogt will serve as interim CDO. CureVac expresses gratitude towards Edvardsen for his contributions, particularly in expanding their pipeline. The company continues to focus on advancing its mRNA technology for various medical applications.
CureVac is enhancing its oncology initiatives through a partnership with myNEO to develop novel mRNA cancer vaccines. This collaboration aims to identify specific tumor antigens that can trigger robust immune responses using myNEO's advanced AI and bioinformatics platform. The agreement focuses on selecting the most promising antigens for clinical testing, leveraging myNEO's genomic data and CureVac's mRNA technology. Both companies aim to build a strong oncology pipeline, expanding beyond existing prophylactic vaccine efforts.
CureVac N.V. (Nasdaq:CVAC) reported significant advancements in its vaccine development, including second-generation candidates for COVID-19 and influenza now in Phase 1 trials. The company is positioned to receive a €10 million milestone payment from GSK for starting its influenza clinical trial. CureVac's cash position is €658.2 million, down from €811.5 million, primarily due to wind-down costs of the CVnCoV vaccine program. Revenues surged 144% to €24.4 million, mainly attributed to collaborations with GSK, while operating loss decreased from €115.8 million to €15.3 million.
CureVac announced its fourth-quarter and full-year 2021 financial results, highlighting a strong cash position of €811.5 million. The company initiated several clinical studies for its second-generation mRNA vaccines targeting COVID-19 and influenza, collaborating with GSK. The CV2CoV candidate is in Phase 1 trials, with promising results from a bivalent vaccine approach. Revenues surged to €103 million, up 111%, driven by GSK collaborations. However, operating losses increased to €412.3 million.
CureVac N.V. (NASDAQ:CVAC) will announce its Q4 and full-year 2021 financial results on April 28, 2022. The event will include a conference call at 3 p.m. CET / 9 a.m. EST. Interested participants can access the call through designated numbers or via a live webcast on the company's website. CureVac specializes in mRNA technology for medical applications, with significant collaborations and a diversified clinical pipeline. The press release emphasizes forward-looking statements regarding future developments, emphasizing the inherent risks associated with such projections.
CureVac, in collaboration with GSK, announced promising preclinical results for a bivalent COVID-19 vaccine candidate targeting the Beta and Delta variants. The study revealed that this bivalent mRNA vaccine generated comparable neutralizing antibody levels to monovalent candidates while demonstrating significantly enhanced neutralization against the Omicron variant. Conducted on mice, the bivalent approach showed strong immune responses and reduced viral loads. This technology could pave the way for broader protection against evolving variants.
CureVac has entered a contract with the German government to ensure mRNA vaccine manufacturing capacity until 2029 in response to potential health emergencies. The agreement allows for the production of up to 80 million doses during public health crises. Following a two-year setup period, the federal government will pay an annual standby fee to keep the manufacturing capacity ready, thereby enhancing pandemic preparedness. This partnership emphasizes the significance of mRNA technology in swiftly addressing future infectious disease threats.
